Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, ...

Sanders, 56, revealed he suffered a heart attack on Father’s Day in 2024 —an event he also discusses in the new Amgen/A&E ...

Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.

Amgen (AMGN) closed at $295.18 in the latest trading session, marking a -1.73% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.33%. Elsewhere, the Dow saw a ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The idea for Amgen’s first foray into documentary film started with two numbers, according to Nerissa Gomes, general manager ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...